Harvey Berger, who co-founded Ariad Pharmaceuticals 23 years ago and oversaw the development and launch of its leukemia drug, Iclusig, is stepping down after months of pressure from shareholders and board members...
Investors seem boyed by Ariad Pharmaceuticals’ decision Friday to adopt a plan designed to prevent takeovers, raising the company’s stock price 22 percent since the Friday morning announcement...
A cancer drug development company that just went public this summer has named the CFO of the biggest biotech around - Biogen Idec Inc. (Nasdaq: BIIB) - as a director...
While Carl Icahn’s team overseeing his investment in Nuance Communications (Nasdaq: NUAN) says they see a lot of promise in the future of voice recognition software, one analyst said the activist investor may try and split the role of CEO from that of chairman in the next two months...
Three directors of cancer drug company Verastem Inc. and its founding executive chairman have purchased $475,000 worth of the company’s stock in the past week as it plans to start a potential pivotal trial against mesothelioma in coming months.
